Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Monitoring of Economic Community of West African States (ECOWAS) Interventions in Benin: The Resident Representation and the ECOWAS National Office Conduct a Joint Monitoring Mission of ECOWAS Projects and Programs in BeninFrom August 31 to September 5, 2026, the Resident Representation of the Economic Community of West African States (ECOWAS) in Benin, in collaboration with the ECOWAS National Office of Benin, conducted a field monitoring mission to assess the progress of projects and programs funded by ECOWAS Agencies and Institutions, identify challenges encountered, and enhance their coordination. Organized into two teams covering the Northern and Southern regions of the country, the mission carried out 20 site visits across 7 interventions in 17 municipalities, as well as 18 institutional audiences with local and prefectural authorities. The visits covered a diverse portfolio of interventions, including revitalizing the local dairy sector, developing forage production, building youth skills and employability in the agricultural and agro-sylvo-pastoral sectors, agroecological training, health, and cross-border cooperation. Field observations highlighted several tangible achievements, particularly improved production and processing capacities for certain dairy units, enhanced technical and entrepreneurial skills among youth, as well as the completion of infrastructure and provision of equipment to support local economic activities. These accomplishments contribute to improving working conditions, strengthening beneficiary capacities, and fostering the growth of production and training activities. The mission also identified challenges related to equipment availability, post-training support for beneficiaries, inter-stakeholder coordination, and the sustainability of achievements. Discussions with municipal authorities emphasized the need to strengthen their involvement in monitoring interventions and to increase the visibility of ECOWAS support among local populations. At the conclusion of the mission, the Resident Representation and the ECOWAS National Office, drawing on their findings, formulated recommendations to strengthen close-range monitoring, improve intervention coordination, and promote the sustainability of results for the benefit of the Beninese population. This effort aligns with the momentum of ECOWAS Vision 2050, which envisions an “ECOWAS of Peoples: Fully Integrated, Peaceful, and Prosperous,” as operationalized in the 2023–2027 Community Strategic Framework. Distributed by APO Group on behalf of Economic Community of West African States (ECOWAS).
- Aquatic Herbicides Market News and Recent Developments in Bio-Herbicide Innovations by 2034Aquatic herbicides are chemical solutions designed to manage and control invasive aquatic plants, algae, and weeds in freshwater and marine ecosystems. These products are widely applied in lakes, rivers, reservoirs, ponds, and irrigation channels to maintain water quality, support irrigation, ... Read more
- All Access"All Access Hosted by Andy Garcia" Explores How Nanomix Group Unlocks the Potential of SiliconThe upcoming segment explores the second most abundant element on earth and why its bioavailable form is critical to living organisms across agriculture, animal health, and human wellness. — An upcoming feature will showcase Nanomix Group and its...
- Five Reputable Agricultural Component Parts Companies in China 2026: Advancing Farm MachineryLogo for Pointiron casting A 2026 guide to five reputable Chinese companies in agricultural component parts manufacturing. CALIFORNIA, CA, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Zhejiang, China, October 22, 2026 — Five Chinese manufacturers supplying component parts for agriculture use are named in a 2026 industry shortlist covering cast hubs, axles, brackets, knuckles, gearbox housings and braking a
- New initiative to help transform livestock sector in low- and middle-income countries launched at 2026 Borlaug DialogueFlagship series will compile evidence and help coordinate efforts across Global South to sustainably improve food and economic security via livestock sector. By launching Livestock Futures at the Borlaug Dialogue, we are placing the sector at the very heart of the global conversation around ending hunger.” — Prof. Appolinaire Djikeng, ILRI Director General DES MOINES, IA, UNITED STATES, October 21, 2026 / EINPresswir
- Levi Strauss & Co.Discovering Levi’s® Link to Canada’s First Black CowboyWidely regarded as Canada’s first Black cowboy, John Ware was born into slavery around 1845 in the southern United States. Following emancipation, he moved to Texas, where he found ranching work and in 1882 was hired to drive 3,000 head of cattle north to the Bar U Ranch in southern Alberta. He remained on the Alberta… The post Discovering Levi’s® Link to Canada’s First Black Cowboy appeared first on Levi Strauss & Co.
- Hyundai Motor CompanyInside the Robot-Run Farm Feeding Singapore’s Families in NeedCompanies: Hyundai Motor Company이전 페이지 Inside the Robot-Run Farm Feeding Singapore’s Families in Need URL copied to clipboard Share via email We do not collect email addresses. Editorials 202609041200 Inside the Robot-Run Farm Feeding Singapore’s Families in Need Share via email We do not collect email addresses. At Hyundai Motor Group Innovation Center Singapore (HMGICS), innovation extends far beyond the production lines. The facility serves as a
- BayerBayer advances combined seed and crop protection pipeline and enters phase of blockbuster launchesCompanies: BayerBayer is implementing its previously announced ambition to bring 10 blockbusters to market over 10 years, beginning to launch major Crop Science innovations in key agricultural regions around the world. A blockbuster is a product that is expected to deliver a peak sales potential of at least 500 million euros. Plenexos™ insecticide and the Preceon™ Smart Corn System have already started to be commercialized. In soy, Vyconic™ 1 is expected for introduction next year in the United States and Canada, and Intacta 5+™1 introduction is expected for the 2027/2028 growing season in Brazil. “We are delivering on the promises we made and bringing a new generation of game-changing products to farmers. By connecting seed and crop protection innovation we can deliver whole-farm solutions that help growers manage risk, capture yield potential and improve return on investment,” said Rodrigo Santos, Member of the Board of Management of Bayer AG and Head of the Crop Science Division. “We pursue a very diligent and differentiated strategy for each of our segments, addressing different growth dynamics, farmer needs, and regional and competitive dynamics. Because we have scale, we see having these different business segments together as a significant strategic advantage – one that plays out in what we innovate and how we can serve growers.” The Preceon™ Smart Corn System, a digitally enabled short-stature corn system, is already delivering on-farm value in Mexico, Italy, Spain, and the U.S. This year, the commercial launch in Argentina will begin. It delivers a unique combination of benefits for growers, including increased protection against weather extremes, flexibility to plant at higher densities, improved accessibility for standard farm equipment throughout the season, and a larger root system, all supporting reduced agronomic risk, higher yield potential and better return on investment for farmers. By 2035, Bayer targets a market penetration of 26 million acres. Preceon™ is also unique by embedding digital capabilities within the system through FieldView™. More than a sales enablement platform, it serves as a collaboration tool between farmers and their agronomic advisors and helps customers realize the full agronomic and economic potential of the system. Plenexos™, a new insecticide targeting a broad spectrum of sucking pests, has been introduced in Colombia, with Mexico, Brazil, and the U.S. set to follow. Compared to other products, farmers can use up to 75 percent less active ingredient to control pests2 which also helps safeguard pollinators, beneficial insects and other non-target organisms. With a focus on soy, cotton, fruits and vegetables, Plenexos™ is anticipated to reach a peak sales potential of 500 million euros by the mid-2030s. Vyconic™ will be the industry's first soybean trait stack with tolerance to five herbicides. It is designed to provide growers with more flexibility in their weed control options and to better manage weed pressure and increasingly problematic resistance. Because of the integration with Bayer’s advanced breeding pipeline, Vyconic™ will be introduced in elite-performing varieties that have demonstrated a yield increase of more than two bushels per acre, meaning that farmers realize the full value of both increased genetic yield potential and weed control flexibility earlier than ever. Bayer anticipates strong adoption of Vyconic™ and subsequent launch of HT5, helping to regain trait leadership position in North America by 2032. Intacta 5+™ will also bring five herbicide tolerances to Brazilian growers, and adds new insect protection traits specifically designed for the Brazilian market. In soy, these and the next generation of herbicide tolerance traits, combined with the newest insect protection traits, are expected to reach a peak sales potential of more than 3 billion euros. Additional blockbusters expected before the end of the decade include fourth-generation corn rootworm protection, as well as the groundbreaking herbicide Icafolin, targeting 750 million euros sales potential in the mid-2030s. Collectively, the 10 blockbusters will address pressing farmer challenges and are poised to contribute significantly to Bayer's growth over the coming decade. Bayer advances industry-leading innovation pipeline Alongside these launches, Bayer advances key projects across its Crop Science R&D pipeline and brings innovation to farmers continuously, introducing 400 to 500 new hybrids and varieties annually. This output is based on Bayer’s AI-enabled precision breeding platform, which doubles the yield improvement rate of every new generation (genetic gain) compared to historical breeding, and accelerates time to market threefold. The company’s researchers have further enhanced this breeding approach through genome editing, which they use at scale by integrating the technology early in breeding processes. One example is genome-edited soy: Higher-yielding soybean varieties can become more susceptible to leaning or falling over as plant height increases. Through genome editing, Bayer is developing soy with improved plant architecture to help address this challenge. Innovations like genome-edited standable soy and the advanced breeding pipeline come together to create new product concepts and value for growers that will come to the market early in the next decade. As another example of its connected R&D engine, Bayer is advancing new biotech traits in concert with its novel crop protection innovation. In early-stage development, the company is working on its sixth-generation herbicide tolerance, which is expected to also include tolerance against its blockbuster herbicide Icafolin. It is the first time the company simultaneously develops a new herbicide molecule and plant trait for tolerance, contributing to a holistic weed-control system that is unique in the industry. Bayer’s AI-powered R&D-CropKey platform is a key differentiator in Crop Protection, enabling the discovery of new modes of action and the design of targeted molecules assessing efficacy, safety, and sustainability at the very start of the R&D process. This has helped create a robust pipeline with more than 15 novel modes of action currently in the pipeline research phase, driven by CropKey. One example is a new broad-spectrum fungicide for soy with blockbuster potential. It is developed using CropKey and now advanced to phase II in the pipeline. “Whether in seeds, traits or crop protection innovation, AI is becoming a core enabler of Bayer’s innovation model, helping us advance discovery, improve development efficiency and translate biological insights into differentiated products for growers faster,” said Mike Graham, Head of Crop Science R&D. “Our advantage is that our teams work from the same biological insights, enabling us to combine expertise across disciplines and accelerate innovation.” Bayer is also using its unique R&D capabilities to expand into adjacent growth areas. With its emergent, but leading portfolio of intermediate biofuel crops, including camelina, winter oilseed rape and CoverCress™, the company contributes to meeting growing demand for biodiesel, renewable diesel and sustainable aviation fuel markets, estimated to increase almost threefold to 40 billion gallons by 2040. Bayer is also advancing its plans to sell hybrid wheat in Europe and North America by the early 2030s. This unlocks a largely untapped opportunity by bringing the benefits of hybridization to a crop grown on more than 500 million acres worldwide. With hybrid wheat, camelina, winter oilseed rape and CoverCress™, Bayer is entering four new crops at the same time. Bayer on track executing its Five-Year Framework Bayer’s innovation approach is enabled by execution of its Five-Year Framework strategy, which the Crop Science Division announced in 2025 to drive growth, resilience and profitability. The company continues to execute the strategy, and efforts are beginning to deliver tangible results. Bayer has made significant progress on cost reductions, amounting to almost 400 million euros to date, contributing to its EBITDA before special items improvement goal of 1 billion euros and supporting its ambition to achieve an EBITDA margin before special items in the mid-20s percentage range by the end of the decade. Actions included divesting five active ingredients and discontinuing more than 100 crop protection formulations. In addition, cash-flow measures are progressing, with inventory reductions of already 500 million euros, supporting Bayer’s ambition to reach a free operating cash flow of more than 3 billion euros by 2029. The Five-Year Framework’s goal of above-market growth and delivering more than 3.5 billion euros of incremental sales at constant currency through the end of the decade is supported by Bayer’s ongoing innovation delivery as well as strategic business decisions. Key growth drivers include excellent-yielding hybrids launched every year, accelerated technology adoption, market share gains and geographic expansion of proven technologies into Asian and EMEA markets. In the crop protection space, Bayer is pursuing growth through locally focused go-to-market initiatives, redeploying commercial resources to growth products and regions, and lifecycle management measures, like the introduction of Convintro™ in the United States, Brazil and Canada. Bayer’s progress is supported by its Dynamic Shared Ownership operating model, which enables faster decisions and clearer accountability, strengthening the company’s ability to lead in scaling AI-enabled opportunities across the business. “Our innovation strategy and our Five-Year Framework are built on execution,” said Rodrigo Santos. “We are making progress against the commitments we have made, and are set to lead the industry and bring value to our customers and shareholders by delivering differentiating solutions that growers around the world need.” Pictures and additional material can be downloaded here. You can find FAQ on this topic here. Notes 1 These products are not currently available for commercial sale or commercial planting. Commercialization is dependent on multiple factors, including successful conclusion of the regulatory process. The information presented herein is provided for educational purposes only, and is not and shall not be construed as an offer to sell. 2 Based upon >600 trials (internal/external) from 2021-2025 in Brazil, including trials with Plenexos™ targeting whiteflies in soybean production; application rate 24 g ai/ha vs. imidacloprid 100 g ai/ha. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. Contact for media inquiries: Alexander Gutmann, phone +49 174 730 6349 Email: [email protected] Benjamin Eberle, phone +1 314 258 6187 Email: [email protected] Contact for investor inquiries: Bayer Investor Relations Team, phone +49 214 30-72704 Email: [email protected] www.bayer.com/en/investors/ir-team
- BayerBayer operationally on track, decisive progress on strategic prioritiesCompanies: BayerThe Bayer Group continued to make headway in the second quarter of 2026, capping off a successful first half of the year. “Operationally, we’re well on track to achieve our full-year outlook,” CEO Bill Anderson said when presenting the company’s Half-Year Financial Report on Tuesday. All three divisions are on target, he noted. Bayer has also made decisive progress on its long-term strategic priorities, Anderson emphasized. The landmark US Supreme Court ruling in the Durnell case is one such example, he said, adding that it puts Bayer in a stronger position for the proposed class settlement agreement. “Overall, our containment strategy is in a strong place, with some important milestones ahead,” Anderson explained. Bayer is also advancing its other strategic priorities, Anderson said, pointing to progress in rejuvenating the Pharmaceuticals pipeline and executing the Five-Year Framework to improve profitability at Crop Science. In addition, Bayer’s lean, entrepreneurial operating model is driving efficiency gains across the entire Group, while also positioning the company well to effectively capitalize on the opportunities of artificial intelligence, he noted. “Over the past two and a half years, we’ve progressed in each of these areas. Each of them has demanded intense focus – and it’s imperative that we maintain that focus,” Anderson emphasized. “We’re concentrating on delivering our commitments and ensuring the best future for Bayer.” Dr. Judith Hartmann, who took over the CFO role in June, shared her perspective. “I am excited to be part of the team driving Bayer forward at such an important time in its journey. While we’ve delivered strong strategic and financial progress, including meaningful steps on our balance sheet, important opportunities remain ahead of us. Bayer benefits from a powerful innovation engine and growth prospects across all three businesses. Our financial priorities are clear: to further strengthen the balance sheet, enhance productivity and improve cash generation, while continuing to invest behind growth and creating sustainable value,” Hartmann said. Sales and EBITDA before special items up against prior year Group sales came in at 10.872 billion euros in the second quarter of 2026, up 2.2 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). There was a negative currency effect of 63 million euros (Q2 2025: 550 million euros). EBITDA before special items increased by 1.9 percent to 2.144 billion euros, and included a negative currency effect of 70 million euros (Q2 2025: 184 million euros). EBIT amounted to 827 million euros (Q2 2025: 13 million euros) after net special charges of 172 million euros (Q2 2025: 981 million euros) that were primarily attributable to litigation-related expenses. Net income came in at 219 million euros (Q2 2025: minus 199 million euros). Core earnings per share decreased by 16.7 percent to 0.95 euros, with the improvement in earnings in the Crop Science Division only partially offsetting a normalization in tax expense and lower earnings in the Reconciliation. Free cash flow amounted to minus 371 million euros (Q2 2025: 125 million euros), partly due to higher payments to resolve litigation. Net financial debt came in at 33.647 billion euros as of June 30, 2026, representing a 3.5 percent increase against March 31, 2026, and a 1.1 percent rise from a year-on-year perspective. Crop Science: Topline growth and efficiencies in cost of goods sold drive higher earnings In the agricultural business (Crop Science), sales increased by 3.5 percent (Fx & portfolio adj.) to 4.910 billion euros. Business was up at Soybean Seed & Traits and Cotton Seed following the return of the dicamba label in the United States, with gains of 16.9 and 69.2 percent (Fx & portfolio adj.), respectively. By contrast, sales at Corn Seed & Traits were down 2.5 percent (Fx & portfolio adj.), with substantial gains in Europe/Middle East/Africa and Asia/Pacific only partially offsetting lower volumes in North America, where business was impacted by volume phasing into the first quarter. In the Crop Protection business, growth was primarily driven by the division’s glyphosate-based herbicides. Sales of these products rose by 12.6 percent (Fx & portfolio adj.) fueled by higher volumes and prices, especially in Europe/Middle East/Africa. The Insecticides business recorded a 15.9 percent (Fx & portfolio adj.) increase in sales that was mainly attributable to higher volumes and prices in Europe/Middle East/Africa and Asia/Pacific. EBITDA before special items at Crop Science advanced by 30.2 percent to 902 million euros. The increase in earnings was largely fueled by high-margin topline growth as well as a decline in the cost of goods sold that was driven by efficiency programs, as the division continues implementation of its Five-Year Framework. The EBITDA margin before special items increased by 3.9 percentage points to 18.4 percent. Pharmaceuticals: Continued growth momentum for Nubeqa™ and Kerendia™ Sales of prescription medicines (Pharmaceuticals) came in at 4.458 billion euros, in line with the prior year (Fx & portfolio adj. plus 0.8 percent). The division again registered significant gains for its cancer drug Nubeqa™, as well as for Kerendia™, its product for the treatment of chronic kidney disease and heart failure. Nubeqa™ sales advanced by 63.9 percent (Fx & portfolio adj.), mainly driven by volume growth in the United States and Europe, while the 82.9 percent (Fx & portfolio adj.) rise in Kerendia™ sales was largely fueled by higher volumes in the United States and China. The Mirena™ product family also delivered very strong topline performance, especially in the United States, with global sales rising 9.0 percent (Fx & portfolio adj.). In the Radiology business, the division recorded gains of 26.8 and 8.1 percent (Fx & portfolio adj.) for Ultravist™ and CT Fluid Delivery, respectively. Business benefited from higher volumes, while prices remained stable. By contrast, Xarelto™ and Eylea™ sales were down significantly, as anticipated. After encountering headwinds from patent expirations, the oral anticoagulant posted a decline of 42.4 percent (Fx & portfolio adj.), while business with the ophthalmology drug decreased 32.8 percent (Fx & portfolio adj.). The Eylea™ 8 mg formulation offering extended treatment intervals accounted for around 55 percent of overall Eylea™ sales. EBITDA before special items at Pharmaceuticals decreased by 3.6 percent to 1.055 billion euros. The decline in earnings was primarily attributable to the division channeling higher investments toward marketing its growth products Lynkuet™ (for the hormone-free treatment of menopause symptoms), Nubeqa™ and Kerendia™. In addition, the prior-year quarter had benefited from proceeds from the sale of non-core businesses. By contrast, earnings benefited from a reduction in allocations to provisions for the Group-wide short-term incentive (STI) program, as well as an inventory write-back. The EBITDA margin before special items decreased by 0.8 percentage points to 23.7 percent. Consumer Health sales up in almost all categories and regions Following a strong first quarter, sales of self-care products (Consumer Health) increased by 1.5 percent (Fx & portfolio adj.) to 1.445 billion euros. Business was up in almost all categories, with Digestive Health delivering the strongest growth, at 9.4 percent (Fx & portfolio adj.). By contrast, sales in the Allergy & Cold category were down 8.0 percent (Fx & portfolio adj.) due to soft seasonality. Regionally, the division continued to face headwinds from a weak market environment in the United States, while business was up year on year in Europe/Middle East/Africa, Latin America and Asia/Pacific. EBITDA before special items at Consumer Health decreased by 3.6 percent to 319 million euros. The decline in earnings was mainly due to an increase in the cost of goods sold and unfavorable product mix effects. These headwinds were only partially offset by the division’s continuous cost and price management efforts. The EBITDA margin before special items declined by 1.1 percentage points to 22.1 percent. Group sales and earnings up in first half of the year In the first six months of 2026, Group sales rose by 3.3 percent (Fx & portfolio adj.) to 24.277 billion euros. EBITDA before special items advanced 6.6 percent to 6.597 billion euros, while core earnings per share increased 3.4 percent to 3.66 euros. Currency-adjusted Group outlook confirmed Bayer has affirmed its currency-adjusted Group guidance for full-year 2026 for all metrics except net financial debt, which it now expects to come in lower than originally projected, at 29 to 30 billion euros (previous forecast: 32 to 33 billion euros). The revised guidance for this KPI reflects the already announced agreement with Apollo-managed funds and affiliates. They will obtain a minority, non-controlling stake in a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business in exchange for a €3.0 billion capital contribution. In addition, applying the closing rates as of June 30, 2026, instead of March 31, 2026, results in the following changes: Group sales are now expected to come in at 44.7 to 46.7 billion euros (44.5 to 46.5 billion euros at previous closing rates), and core EPS at 4.20 to 4.70 euros (4.10 to 4.60 euros at previous closing rates). Notes: The following tables contain the key data for the Bayer Group and its divisions for the second quarter and the first six months of 2026. The full Half-Year Financial Report is available online at: www.bayer.com/halfyearreport. There is also a digital version available. The speech given by Bill Anderson and Dr. Judith Hartmann to the media will be available online from around 9 a.m. CEST at: www.bayer.com/speeches Live broadcast of the Media Update from around 9 a.m. CEST and recording available from around 12 p.m. CEST at: www.bayer.com/live-mc Additional information for investors, including presentation charts, and access to the live broadcast of the Investor Video Call (from around 2 p.m. CEST) and recording (from around 6 p.m. CEST) available at: www.bayer.com/live-ic Print-quality photos can be found online at: www.bayer.com/photo-footage You can find FAQ on this topic here. Find more information at www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.
- BayerBayer signs licensing agreement with RAGT and begins broad hybrid wheat commercialization by early 2030sCompanies: BayerBayer enters an exclusive licensing agreement with RAGT, a leading company in the European wheat seed market, advancing its plans to sell hybrid wheat seeds in Europe and North America simultaneously by the early 2030s. Hybrid wheat represents a large, untapped opportunity in the world’s most widely grown food crops and Bayer targets annual revenues of up to 1 billion euros after just over a decade after launch. The move is part of Bayer's growth ambitions beyond its current blockbuster launches by expanding its core portfolio to hybrid wheat as a key franchise. The new agreement with RAGT materially strengthens Bayer’s position in Europe, as it involves the broad licensing of elite wheat germplasm tailored for European environments. This gives Bayer the ideal foundation to further advance and deploy its powerful breeding engine based on its longstanding hybrid wheat R&D efforts, to develop innovations that provide greater productivity and sustainability to farmers at a time when many face challenging weather and growing conditions. “Wheat is one of the most important staple food crops in the world. But wheat production has stagnated and is coming under pressure from prolonged drought and heatwaves, such as the one we just experienced in Europe. At the same time, sturdier hybrid varieties of wheat are still not widely available,” said Peter Mueller, Cereals, Cotton, Canola/OSR & Biofuels Lead at Bayer’s Crop Science division. “Our deal with RAGT is about to change that. Combining RAGT’s top performing germplasm and know-how with our breeding capabilities will significantly boost and expand our pipeline of hybrid wheat varieties, allowing us to compete in a rapidly evolving market. With the North American program in full gear, we will deliver higher value to growers on both sides of the Atlantic.” Sébastien Chatre, Head of R&D at RAGT added, “We’re very excited about the potential of this broad licensing agreement with Bayer, as it represents a significant step in RAGT’s commitment to innovation in wheat breeding. By sharing our expertise, we can accelerate the development of hybrid wheat solutions that will benefit the entire market and meet the evolving needs of farmers and the seed industry.” For the European market, Bayer will focus its efforts on winter wheat. In North America, the company will introduce both spring and winter wheat, building on its successful WestBred wheat franchise. In both Europe and the U.S., the genetic material Bayer uses for breeding has the potential to fit in more than 80 percent of the wheat hectares, spanning across countries in Europe and across classes in the U.S. Bayer’s leading position in the crop protection space for wheat and the respective customer relations, combined with its access to elite germplasm for Europe and North America, precision breeding capabilities, seed production know-how, as well as digital and agronomic expertise will help the company build a competitive, holistic wheat system for farmers. Hybrid wheat to deliver higher yields Hybrid wheat seeds can increase wheat production without additional land or resource use, adding 10 percent compared to conventional open-pollinated wheat, right from the early stages of introduction of the new technology, with continuous additional yield gains going forward. Additional benefits for farmers include more reliability and robustness because key attributes of hybridization include an enhanced root system and faster growth to establish a strong crop against external factors, leading to potential better disease, weed and pest tolerance, and greater resilience to drought and heat. With hybridization of wheat still largely untapped, investing in hybrid wheat presents a unique opportunity for growth and enhanced food security. As the world’s number one food crop, wheat covers over 220 million hectares globally and feeds around 30 percent of the population, making it an essential source of the world’s calories and a staple crop for fighting hunger. With climates in wheat-growing regions becoming hotter and drier, demand is continuing to increase further for resilient hybrid seeds that offer higher and more stable yields. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.
- BayerMonsanto wins landmark Roundup™ case at U.S. Supreme CourtCompanies: BayerThe U.S. Supreme Court issued a 7:2 landmark ruling in the Durnell Roundup™ case on Thursday, affirming that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state-law-based failure-to-warn claims when the U.S. Environmental Protection Agency (EPA) has made a definitive determination on product safety. This decision, which reflects strong support across the ideological spectrum of the Court, helps to bring significant containment to the Roundup™ litigation. Glyphosate remains the most studied crop protection tool in the world and this decision affirms that the EPA’s safety determination is the law of the land, ensuring that companies cannot be punished under a patchwork of state tort laws for complying with federal labeling requirements. “This decision is good for American farmers who help feed the world. It provides the regulatory clarity necessary for innovators like us to develop the agricultural tools that guarantee an affordable food supply,” said Bayer CEO Bill Anderson. "This litigation has enormous costs for the company and has impacted public trust. The decision brings overdue justice on an issue that should have been clarified much earlier. It’s time to put it behind us. Strengthened by this ruling, we continue to pursue our multi-pronged containment strategy, which includes the previously announced class settlement.” The majority opinion states: “Durnell’s state law failure-to-warn claim would require a cancer warning on Roundup’s label — a requirement ‘in addition to’ and ‘different from’ the label required by EPA under FIFRA. FIFRA therefore expressly preempts Durnell’s claim.” Impact of the Ruling The holding in Durnell should result in the dismissal of current warnings-based claims and foreclose future claims based on state-failure-to-warn theories, which make up the vast majority of claims in the litigation to date. In February 2026, along with class counsel, Monsanto announced a proposed U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin lymphoma injuries through a long-term compensation program. Monsanto previously explained that the class settlement and Supreme Court strategies were independently necessary and mutually reinforcing elements of the company’s multi-pronged containment strategy. Together with today’s positive ruling, the class – which has received preliminary approval – will help ensure that Monsanto can significantly contain this litigation. Good for farmers, food security, and American consumers For years, American farmers have operated under a cloud of legal uncertainty created not by science, but by the litigation industry. Glyphosate-based herbicides are a foundation of modern, sustainable agriculture. Their safe and effective use supports food security, keeps production costs affordable, makes no-till, sustainable farm practices possible, and allows farmers to do more with less. This ruling restores the regulatory clarity that the agricultural sector, the broader food supply chain, and American consumers deserve after nearly a decade of well-funded attacks by the plaintiffs’ bar. It also provides an opportunity to restore public trust in the scientific consensus on the safety of glyphosate-based herbicides. The studies reviewed by regulatory authorities on glyphosate’s safety in connection with recent registration reviews are publicly available at www.bayer.com/en/glyphosate-studies Court clarifies law that supports science The EPA has repeatedly and unequivocally determined that glyphosate is not likely to be carcinogenic. Every leading independent regulatory body worldwide that has conducted its own review of glyphosate safety — from the European Food Safety Authority to regulators across Asia and Latin America — has reached the same conclusion. This is not the judgment of any single agency or administration; it is the settled consensus of the world's foremost scientific experts. What has challenged this consensus is not new evidence — instead, it is largely a single, decade-old report from the International Agency for Research on Cancer (IARC) used in courtrooms by plaintiffs’ attorneys, despite the fact that every leading regulator in the world that has examined IARC’s report disagrees with its conclusions. Allowing this outlier report to override the expert determinations of federal regulatory agencies and scientists, despite the express uniformity requirements of federal law, has led to a patchwork of jury-by-jury requirements and uncertainties for manufacturers, farmers, and consumers alike. This decision restores the integrity of the scientific regulatory process and the independence of the experts within it. The long road to this moment This litigation has spanned years, consumed enormous resources, and distracted from what the company does best — promoting Health for all, Hunger for none. Many billions have been directed toward the Roundup™ litigation — money that could have funded the next generation of sustainable crop protection tools, breakthrough therapies, or other advances that farmers, consumers, and patients urgently need. These litigation costs diminish investments in innovation and are borne not just by the company, but by every patient waiting for a new therapy, every farmer waiting for a better tool, and every shareholder whose capital was diverted. Today marks the beginning of a new chapter in Health for all, Hunger for none. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.
- BayerBayer reports solid start to the year and confirms currency-adjusted Group guidance for 2026Companies: BayerThe Bayer Group has reported a solid performance across all divisions for the first quarter of 2026. “We’re pleased with how our businesses started the year and we’re confirming our currency-adjusted outlook for 2026,” CEO Bill Anderson said when presenting the company’s Quarterly Statement for the first quarter on Tuesday. Commenting on the company’s strategic priorities, he explained that “we continue to advance our plan and we’re dialed in on delivering our commitments in the current year.” Group sales came in at 13.405 billion euros in the first quarter of 2026, up 4.1 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). There was a negative currency effect of 886 million euros (Q1 2025: 55 million euros). EBITDA before special items increased by 9.0 percent to 4.453 billion euros. This figure included a negative currency effect of 321 million euros (Q1 2025: 165 million euros). EBIT rose by 51.8 percent to 3.528 billion euros after net special gains of 324 million euros (Q1 2025: net special charges of 587 million euros) that mainly related to the sale of the global Avelox™ business for 250 million euros. Net income came in at 2.763 billion euros, and was therefore more than two times higher than a year earlier. Core earnings per share climbed 12.9 percent to 2.71 euros, largely driven by the increase in earnings at the Crop Science Division. However, growth was partially held back by a negative currency effect of 0.20 euros (Q1 2025: 0.13 euros). Free cash flow came in at minus 2.320 billion euros (Q1 2025: minus 1.528 billion euros). This was mainly attributable to payments to resolve legal proceedings, which increased as expected and largely related to the PCB and glyphosate litigations. Overall, these payments resulted in a net outflow of 2.002 billion euros (Q1 2025: 66 million euros). Net financial debt as of March 31, 2026, came in at 32.518 billion euros, up 9.0 percent from December 31, 2025, as a result of the negative free cash flow. Compared to March 31, 2025, however, net financial debt was down 5.1 percent. Crop Science posts gains in seed and traits In the agricultural business (Crop Science), sales increased by 6.8 percent (Fx & portfolio adj.) to 7.558 billion euros. Growth was mainly driven by Soybean Seed & Traits, which saw sales double (Fx & portfolio adj.) largely due to the previously announced resolution of a licensing agreement with Corteva in North America, with this effect contributing the equivalent of 448 million euros to the topline. The Soybean Seed & Traits business also benefited from price recovery following the return of the dicamba label in the United States. In addition, the division posted a gain of 7.1 percent (Fx & portfolio adj.) at Corn Seed & Traits that was fueled by higher volumes at the start of season in North America and growth across all other regions as well. By contrast, the crop protection business declined, as expected. At Herbicides, for example, sales were down 10.2 percent (Fx & portfolio adj.) overall, with glyphosate-based products experiencing a 15.1 percent decline (Fx & portfolio adj.). In addition, sales at Fungicides decreased 10.7 percent (Fx & portfolio adj.). EBITDA before special items at Crop Science rose by 17.9 percent to 3.014 billion euros. Strong growth in the Soybean Seed & Traits and Corn Seed & Traits businesses, as well as a decrease in the cost of goods sold due to efficiency programs more than offset the negative currency effect of 277 million euros (Q1 2025: 26 million euros). The EBITDA margin before special items increased by 6.2 percentage points to 39.9 percent, in line with the strategic objectives of the Five-Year Framework announced in 2025. Pharmaceuticals records further significant gains for Nubeqa™ and Kerendia™ Sales of prescription medicines (Pharmaceuticals) came in at 4.249 billion euros, in line with the prior year (Fx & portfolio adj. minus 0.5 percent). The division again registered significant gains for Nubeqa™, the cancer drug, and Kerendia™, for the treatment of chronic kidney disease and heart failure. Nubeqa™ sales advanced 57.1 percent (Fx & portfolio adj.) thanks to higher volumes in the United States and Europe, while Kerendia™ sales were up 84.2 percent (Fx & portfolio adj.) due to volume growth in the United States and China. In addition, the division posted further gains in the Radiology business, which includes products such as Ultravist™ and CT Fluid Delivery, with growth driven by higher volumes. By contrast, sales of the oral anticoagulant Xarelto™ declined substantially as expected, falling 40.4 percent (Fx & portfolio adj.) due to patent expirations, while business with the ophthalmology drug Eylea™ was down 20.5 percent (Fx & portfolio adj.) as a result of competitive pressure from generics. The launch of Eylea™ 8 mg offering extended treatment intervals accounted for around 46 percent of overall Eylea™ sales. EBITDA before special items at Pharmaceuticals declined by 7.5 percent to 1.242 billion euros. The decline in earnings was largely due to an increase in selling expenses that primarily related to the marketing of Lynkuet™ (elinzanetant), Bayer’s non-hormonal treatment for menopause symptoms, as well as Nubeqa™ and Kerendia™. Furthermore, the division made higher investments in its R&D activities. In addition, earnings were diminished by price declines, which were mainly attributable to patent expirations and were only partially offset by higher volumes. There was also a negative currency effect of 77 million euros (Q1 2025: 48 million euros). By contrast, earnings benefited from an increase in income from the sale of non-core businesses as well as lower inventory write-offs. The EBITDA margin before special items declined by 0.3 percentage points to 29.2 percent. Consumer Health reports topline growth (Fx & portfolio adj.) driven by Nutritionals and Dermatology Sales of self-care products (Consumer Health) rose by 5.3 percent (Fx & portfolio adj.) to 1.491 billion euros. The division registered gains (Fx & portfolio adj.) in almost all categories and regions. Performance was driven by the Nutritionals and Dermatology categories, which saw sales rise 12.5 percent and 9.6 percent (Fx & portfolio adj.), respectively. Growth in the Nutritionals category was fueled by very strong performance in the Natsana e-commerce business, along with good topline results for Elevit™ that were partly driven by a product-line extension. The Dermatology category continued to benefit from substantial gains for Bepanthen™ in Europe/Middle East/Africa. However, the division continued to encounter a weak market environment in the United States, along with a soft cold season, that weighed on growth. EBITDA before special items at Consumer Health decreased by 1.5 percent to 337 million euros. Earnings were impacted by a negative currency effect of 31 million euros (Q1 2025: no material currency effects) and higher investments in marketing the division’s innovative products. These effects were largely offset by the increase in sales as well as a one-time gain from the sale of minor, non-strategic brands. The EBITDA margin before special items declined by 0.2 percentage points to 22.6 percent. Currency-adjusted guidance confirmed Commenting on the company’s expectations for the year, CFO Wolfgang Nickl said: “We reiterate our outlook at constant currencies for the full-year 2026, while continuing to monitor the geopolitical dynamics.” Bayer has also prepared its guidance based on closing-day rates. Applying the rates in effect on March 31, 2026, the company now expects sales to come in at 44.5 to 46.5 billion euros (previous forecast: 44 to 46 billion euros), EBITDA before special items at 9.4 to 9.9 billion euros (previous forecast: 9.1 to 9.6 billion euros) and core earnings per share at 4.10 to 4.60 euros (previous forecast: 4.00 to 4.50 euros), with the changes solely reflecting the impact of currency effects. “This is just a point-in-time analysis,” noted Nickl, adding that “we would still expect ongoing volatility around foreign exchange rate developments for the rest of this year.” Notes: The following tables contain the key data for the Bayer Group and its divisions for the first quarter of 2026. The full Quarterly Statement for the first quarter is available online at: www.bayer.com/quarterly-statement. There is also a digital version available. The speech given by Bill Anderson and Wolfgang Nickl to the media will be available online from around 10 a.m. CEST at: www.bayer.com/speeches Live broadcast of the media update from around 10 a.m. CEST and recording available from around 1 p.m. CEST at: www.bayer.com/live-mc Additional information for investors, including presentation charts, and access to the live broadcast of the Investor Video Call (from around 2 p.m. CEST) and recording (from around 6 p.m. CEST) available at: www.bayer.com/live-ic Print-quality photos can be found online at: www.bayer.com/photo-footage Find more information at www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.